FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:95-97 July 2, 2009 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Van Cutsem, E. PubMed Citation

To the Editor: As a gastroenterologist who claims to have been the first physician in Connecticut to give fluorouracil to a patient with colon cancer, I was delighted to read in the Conclusions of the Abstract of the article by Van Cutsem et al. (April 2 issue)¹ that "First-line treatment with cetuximab plus FOLFIRI [irinotecan, fluorouracil, and leucovorin], as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer." My enthusiasm was tempered when I then read in the Results of the Abstract — and in the body of the article — that "There was no significant . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.